For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Goodfellow gems #73
Wednesday 28 February 2018, 12:00 AM
“Hydrolysed no different from conventional formula for infants at risk for type 1 diabetes”
A controlled trial across 15 countries studied 2159 infants who had human leukocyte antigen disease susceptibility and a first-degree relative with ty
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.